TY - JOUR
T1 - Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: Single-institution experience and systematic review
AU - Tagliaferri, Luca
AU - Bussu, Francesco
AU - Fionda, Bruno
AU - Catucci, Francesco
AU - Rigante, Mario
AU - Gambacorta, Maria Antonietta
AU - Autorino, Rosa
AU - Mattiucci, Gian Carlo
AU - Miccichè, Francesco
AU - Placidi, Elisa
AU - Balducci, Mario
AU - Galli, Jacopo
AU - Paludetti, Gaetano
AU - Kovacs, György
AU - Valentini, Vincenzo
N1 - Publisher Copyright:
© 2017 Wichtig Publishing.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/8/3
Y1 - 2017/8/3
N2 - Aim: The aim of our study was to evaluate the outcomes of patients reirradiated with high-dose-rate (HDR) intensity-modulated brachytherapy (IMBT) for recurrent head and neck cancer and to perform a systematic review of the literature. Materials and methods: Patients treated with prior radiation doses > 65 Gy were considered. After resection of macroscopic disease, catheters were fixed to the tumor bed. The total dose was 30 Gy in 12 fractions of 2.5 Gy twice daily for 5 days a week. A systematic literature search was conducted through several electronic databases including Medline/PubMed, Scopus, Embase and the Cochrane library. Results: Seventeen patients were included; median overall survival was 19 months with a median local control interval of 15 months. Median follow-up was 36 months. Seven papers were considered for the review. Conclusions: IMBT could play an important role in the retreatment of recurrent head and neck cancer.
AB - Aim: The aim of our study was to evaluate the outcomes of patients reirradiated with high-dose-rate (HDR) intensity-modulated brachytherapy (IMBT) for recurrent head and neck cancer and to perform a systematic review of the literature. Materials and methods: Patients treated with prior radiation doses > 65 Gy were considered. After resection of macroscopic disease, catheters were fixed to the tumor bed. The total dose was 30 Gy in 12 fractions of 2.5 Gy twice daily for 5 days a week. A systematic literature search was conducted through several electronic databases including Medline/PubMed, Scopus, Embase and the Cochrane library. Results: Seventeen patients were included; median overall survival was 19 months with a median local control interval of 15 months. Median follow-up was 36 months. Seven papers were considered for the review. Conclusions: IMBT could play an important role in the retreatment of recurrent head and neck cancer.
UR - http://www.scopus.com/inward/record.url?scp=85037109713&partnerID=8YFLogxK
U2 - 10.5301/tj.5000614
DO - 10.5301/tj.5000614
M3 - Scientific review articles
C2 - 28291904
AN - SCOPUS:85037109713
SN - 0300-8916
VL - 103
SP - 516
EP - 524
JO - Tumori
JF - Tumori
IS - 6
ER -